Q3 2009 LeMaitre Vascular, Inc. Earnings Release - After Market Close

Earnings Announcements for Wednesday, October 28CompanySymbolTimeConferenceCall8x8, Inc.EGHTAfter Market CloseACC LTDACC.BOTime Not SuppliedACCO BrandsABDBefore Market OpenListenAcerinoxACX.MCTime Not SuppliedActa Holding ASAACTA.OL03:30 am ETAcxiomACXMAfter Market CloseAdvance America, Cash Advance Centers Inc.AEAAfter Market CloseADVANCED ANALOG TECH INC3438.TWOAfter Market CloseAdvanced Analogic TechnologiesAATIAfter Market CloseAdvanced Energy IndustriesAEISBefore Market OpenAdvantest CorpATE02:00 am ETAEROSUN CORPORATION600501.SSTime Not SuppliedAffiliated Managers Group, Inc.AMGTime Not SuppliedListenAflac IncorporatedAFLAfter Market CloseListenAgnico-Eagle Mines LimitedAEMAfter Market CloseAkamai Technologies Inc.AKAMAfter Market CloseListenAKTIV KAPITAL ASA...
Click here to read the whole Article (external link)

LeMaitre Vascular Q3 2009 Record Sales $13.3mm (up 11%), Op. Profit $1.3mm

BURLINGTON, Mass., Oct. 28, 2009 (GLOBE NEWSWIRE) -- LeMaitre Vascular, Inc. (Nasdaq:LMAT - News), a provider of peripheral vascular devices and implants, today announced Q3 2009 financial results, posting record quarterly sales of $13.3 million, record operating income of $1.3 million and increased cash and marketable securities of $2.9 million. The Company also increased its 2009 top- and bottom-line guidance while doubling its stock repurchase program from $1 million to $2 million. Q3 2009 sales were $13.3 million, an 11% increase versus Q3 2008. On an organic basis, Q3 2009 sales increased 10% versus the prior year, while the Vascular category increased 16%, Endovascular increased 1% and General Surgery decreased 2%. Geographically, organic sales grew 8% in the Americas, 12% in Europe and 21% in Japan. The Company reported a gross margin of 73.0% in Q3 2009, up from 67.4% in Q3 2008. The increase over the prior period was driven by lower inventory write-downs, manufacturing efficiencies, and higher average selling prices. Q3 2009 operating profit was $1.3 million versus $170,000 in Q3 2008. Sales growth coupled with an expanded gross margin drove this $1.1 million improvement. Net income in Q3 2009 was $1.3 million, or $0.08 per diluted share, versus a net loss of $136,000 in Q3 2008, or ($0.01) per diluted share. The Company's cash and marketable securities increased by $2.9 million during the quarter to $22.7 million at September 30, 2009. This increase was largely the resul...
Click here to read the whole Article (external link)

LeMaitre Vascular Q3 2009 Earnings Call Transcript

LeMaitre Vascular, Inc. (LMAT) Q3 2009 Earnings Call October 28, 2009 17:00 pm ET Executives Joseph P. Pellegrino Jr. – CFO George W. LeMaitre – Chairman and CEO David B. Roberts – President Analysts Mayank Gandhi (ph) - Cowen & Co. Larry Haimovitch - HMTC Jeff Englander - Standard & Poor's Presentation Operator Welcome to the LeMaitre Vascular third quarter 2009 financial results conference call. As a reminder, this call is being recorded. At this time I would like to turn the call over to Mr. J.J. Pellegrino, Chief Financial Officer of LeMaitre Vascular. Please go ahead, sir. Joseph P. Pellegrino Jr. Thank you, Chris. Good afternoon and thank you for joining us for our Q3 2009 conference call. Joining me on today’s call is our Chairman and CEO, George LeMaitre and our President, Dave Roberts. Before we begin I would like to read our Safe Harbor statement. Today we will discuss some forward-looking statements, the accuracy of which is subject to risks and uncertainties. Wherever possible we will try to identify those forward-looking statements by using words such as; belief, expect, anticipate, forecast and similar expressions. Please note these words are not the exclusive means for identifying such statements. Please refer to the cautionary statements regarding forward-looking information and the information under the caption, risk factors, in our 2008 10-K and subsequent SEC filings, including disclosure of the factors that could cause actual results to differ materially from those expressed or implied. I’ll now turn the call over to George LeMaitre. George W. LeMaitre...
Click here to read the whole Article (external link)

LeMaitre Vascular, Inc. Earnings Call scheduled for 5:00 pm ET today

Call DetailsLeMaitre Vascular, Inc. Earnings Conference Call (Q3 2009)Wed, Oct 28, 2009, 5:00 pm EasternAbout LeMaitre Vascular, Inc. (NasdaqGM:LMAT)LeMaitre Vascular, Inc. develops, manufactures, and markets medical devices and implants for the treatment of peripheral vascular disease. The company’s products include TAArget Thoracic Stent Graft for use in the repair of thoracic aortic aneurysm and dissection; UniFit Abdominal Stent Graft for abdominal aortic aneurysm; aSpire Covered Stent for holding open major leg arteries that have had blockages removed; LeverEdge Contrast Injector for injection of media to monitor blood flow and determine vessel location; VascuTape Radiopaque Tape for the improvement of endovascular procedures; AnastoClip Vessel Closure System for the attachment of blood vessels, primarily for dialysis access; and Albograft Vascular Graft for use in bypass and replacement procedures. Its products also include EndoRE Remote Endarterectomy Devices for removal of blockages in the major arteries of the leg; InvisiGrip Vein Stripper, a Single-incision removal of varicose veins; Expandable LeMaitre Valvulotome for destructing vein valves to create vein bypass graft; Pruitt-Inahara, Pruitt F3, and Flexcel Carotid Shunts for the facilitation of blood flow to brain during carotid plaque removal; LeMaitre Balloon Catheters for the removal of blood clots, occlusion, and facilitation of blood flow; OptiLock Implantable Port, a central venous infusion of drugs and nutrients; and Reddick Cholangiogram Catheter for the introduction of dye into the cystic duct. It sells its products to vascular surgeons and interventionalists through direct sales force and a network of distributors primarily in North America, the European Union, and Japan. The company was formerly known as Vascutech, Inc. and changed its name to LeMaitre Vascular, Inc. in April...
Click here to read the whole Article (external link)

LEMAITRE VASCULAR INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exh

Show all filings for LEMAITRE VASCULAR INC | Request a Trial to NEW EDGAR Online Pro Form 8-K for LEMAITRE VASCULAR INC 28-Oct-2009Results of Operations and Financial Condition, Financial Statements and Exh Copyright © 2009 Yahoo! Inc. All rights reserved. Privacy Policy - Terms of Service - Copyright/IP Policy - Send Feedback SEC Filing data and information provided by EDGAR Online, Inc. (1-800-416-6651). All information pro...
Click here to read the whole Article (external link)

Revlon, Micromet: Early Volume Plays

Stock quotes in this article: LMAT , MITI , MHGC , ...
Click here to read the whole Article (external link)

Early-Market Movers: Akamai,Motorola

Stock futures were moving higher indicating a strong open after a 3.5% jump in gross domestic products in the third quarter and a drop in jobless claims. Here are some of the early-market movers for Thursday.  Akamai Technologies Inc. (AKAM) Shares were up 7.9% in pre-market trading Thursday after third-quarter results were released after the bell Wednesday, which beat analyst expectations. Earnings, excluding items, were reported at 25 cents per share on revenue of $206.5 million. Analysts had estimated earnings of 35 cents per share on $199.4 million in revenue.  American Superconductor Corp (AMSC) The company released second-quarter results beating analyst estimates reporting earnings of 19 cents per share and revenue of %74.74 million. Analysts had been expecting earnings of 13 cents per share and revenue of $69 million. Quarterly revenue was up 85% and the company raised guidance for the remainder of the fiscal year. Shares were up 14% in pre-market trading. Lemaitre Vascular Inc. (LMAT) Shares of the medical device manufacturer were up 9.9% in pre-market trading after the company posted third-quarter results which beat analyst expectations. The company reported earnings of 8 cents per share on revenue of $13.3 million. Analysts had been expecting earnings of 1 cent per share on revenue of $11.8 million.  Motorola Inc. (MOT) The company swung to a third-quarter profit reporting earnings of 1 cent per share on revenue of $5.45 billion. Analysts had been expecting the company to break even...
Click here to read the whole Article (external link)

LeMaitre Vascular to Present at Canaccord Adams 3rd Annual Cardiovascular Conference

LeMaitre Vascular to Present at Canaccord Adams 3rd Annual Cardiovascular Conference - Yahoo! Finance.gnwlistitemmarginbottom {margin-bottom: 10.0px} .gnwtablebottommargin {margin-bottom: 10.0px} .gnwcellpaddingleft0 {padding-left: 0.0px} .gnwverticalaligntop {vertical-align: top} .gnwtextaligncenter {text-align: center} .gnwcellparagraphmargin {margin-bottom: 0px; margin-top: 0px} .gnwverticalalignbottom {vertical-align: bottom} .gnwwhitespacenowrap {white-space: nowrap} .gnwtextalignright {text-align: right} .gnwcellpaddingright0 {padding-right: 0.0px} .gnwunderlinestyle {text-decoration: underline} .gnwtextalignleft {text-align: left} .gnw_heading {font: 16px Arial; text-align: center} .gnw_subhead {font: 12px Arial; text-align: center} .gnw_colhead {font: 12px Arial; text-align: center} .gnw_colhead_uline {font: 12px Arial; text-align: center; border-bottom: solid black 1.0pt;} .gnw_colhead_dline {font: 12px Arial; text-align: center; border-bottom: double black 2.5pt;} .gnw_label {font: 12px Arial; vertical-align: bottom; text-align: left } .gnw_label_uline {font: 12px Arial; vertical-align: bottom; text-align: left; border-bottom: solid black 1.0pt;} .gnw_label_uline_i10 {font: 12px Arial; vertical-align: bottom; text-align: right; border-bottom: solid black 1.0pt;} .gnw_label_uline_i15 {font: 12px Arial; vertical-align: bottom; text-align: right; border-bottom: solid black 1.0pt;} .gnw_label_uline_i20 {font: 12px Arial; vertical-align: bottom; text-align: right; border-bottom: solid black 1.0pt;} .gnw_label_uline_i25 {font: 12px Arial; vertical-align: bottom; text-align: right; border-bottom: solid black 1.0pt;} .gnw_label_uline_i30 {font: 12px Arial; vertical-align: bottom; text-align: right; border-bottom: solid black 1.0pt;} .gnw_label_dline {font: 12px Arial; vertical-align: bottom; text-align: left; border-bottom: double black 2.5pt;} .gnw_label_i10 {font: 12px Arial; vertical-align: bottom; text-align: left; padding-left: 10.0px;} .gnw_label_i15 {font: 12px Arial; vertical-align: bottom; text-a...
Click here to read the whole Article (external link)

LEMAITRE VASCULAR INC Files SEC form 10-Q, Quarterly Report

Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations This Quarterly Report on Form 10-Q contains forward-looking statements (within the meaning of the federal securities law) that involve substantial risks and uncertainties. All statements, other than statements of historical facts, included in this Quarterly Report on Form 10-Q regarding our strategy, future operations, future financial position, future net sales, projected costs, projected expenses, prospects, and plans and objectives of management are forward-looking statements. The words "anticipates," "believes," "estimates," "expects," "intends," "may," "plans," "projects," "will," "would," and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. We have based these forward-looking statements on our current expectations and projections about future events. Although we believe that the expectations underlying any of our forward-looking statements are reasonable, these expectations may prove to be incorrect, and all of these statements are subject to risks and uncertainties. Should one or more of these risks and uncertainties materialize, or should underlying assumptions, projections, or expectations prove incorrect, actual results, performance, or financial condition may vary materially and adversely from those anticipated, estimated, or expected. We have identified below some important factors that could cause our forward-looking statements to differ materially from actual results, performance, or financial conditions: • the unpredictability of our quarterly net sales and results of operations; • the ability to keep pace with a rapidly evolving marketplace and to develop or acquire and then successfully market new and enhanced products; • our ability to successfully id...
Click here to read the whole Article (external link)